Infinity Regains Rights To Its Lead Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.
You may also be interested in...
Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.
Patient Deaths Stop Infinity Pharma’s Phase III HSP90 Trial In Cancer
Sicker patients may have led to result in GI stromal tumors; lung, breast studies with IPI-504 continue.
Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer
Infinity Pharmaceuticals' decision to pull the plug on the registrational Phase III trial with heat shock protein 90 inhibitor IPI-504 - the only product not part of the broad-ranging deal with affiliated specialty pharmas Purdue and Mundipharma - put a chill into investors April 15